However, multiple retrospective analyses report that the status of the PBRM1 mutation is not associated with the clinical benefit of various ICI in other solid tumor types, including non-small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of loss of function of PBRM1 may depend on the type of tumor (38). The gene discussed is PBRM1; the disease is melanoma.